Diamond Biofund Inc is a Taiwan-based company primarily engaged in the venture capital and general investment industries. The Company focuses on investments in the biotechnology and medical fields. Main investment areas include new drug research and development, high-end medical devices, innovative medical service technologies or models, medical access, and agricultural biotechnology. The Company's investments are primarily in the domestic sector.

Employees

Sector

Investment Management & Fund Operators

More about the company

Quotes

Date	Price	Change	Volume
26-08-12	NT$16.90	+0.30%	3,765,013
26-08-11	NT$16.85	+3.37%	5,375,340
26-08-10	NT$16.30	-9.19%	7,060,030
26-08-07	NT$17.95	+2.57%	3,162,584
26-08-06	NT$17.50	-0.57%	1,203,073

End-of-day quote Taiwan S.E.

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Taiwan S.E. 2026-08-12			5-day change	1st Jan Change
16.90 ^TWD	+0.30%		-3.98%	+2.42%

08-11	Diamond Biofund Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-05	Diamond Biofund Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	14.41B 447M 387M 363M 331M 622M 42.63B 632M 4.27B 1.67B 21.34B 1.68B 1.64B 71.17B	P/E 2024	-11x	P/E 2025	-12x
Enterprise Value	10.62B 329M 285M 267M 244M 458M 31.4B 465M 3.14B 1.23B 15.72B 1.24B 1.21B 52.42B	EV / Sales 2024	-10.2x	EV / Sales 2025	-9.56x
Free-Float	16.25%	Yield 2024 *	-	Yield 2025	-

08-11	Diamond Biofund Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-05	Diamond Biofund Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-12	Diamond Biofund Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-22	Diamond Biofund Inc. Announces Financial Officer Changes, Effective December 22, 2025	CI
11-10	Diamond Biofund Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-07	Diamond Biofund Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-05-09	Diamond Biofund Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-02-25	Diamond Biofund Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-12-10	Diamond Biofund Logs Negative Revenue for Three Straight Months	MT
24-11-11	Diamond Biofund Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
24-08-09	Diamond Biofund Incurs Over NT$941 Million Loss in H1	MT
24-08-09	Diamond Biofund Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
24-08-08	Stemcyte International, Inc. announced that it expects to receive $19.05 million in funding from Diamond Biofund Inc.	CI

1 day	+0.30%
1 week	-3.98%
Current month	+3.68%
1 month	-18.55%
3 months	+25.65%
6 months	+5.30%
Current year	+2.42%

Diamond Biofund Inc. Stock

Stocks

6901

TW0006901002

Investment Management & Fund Operators

Valuation: Diamond Biofund Inc.

Chart: Diamond Biofund Inc.

Latest news : Diamond Biofund Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Diamond Biofund Inc.

Other Investment Management & Fund Operators

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	16	18.7
1 month	15.75	19.7
Current year	12.05	22.4
1 year	12.05	22.4
3 years	12.05	72.7
5 years	12.05	200.19
10 years	12.05	200.19

Manager	Title	Age	Since
Shu Ling Cheng CEO	Chief Executive Officer	-	-
Yuan Ting Wu DFI	Director of Finance/CFO	-	-

Director	Title	Age	Since
Kung Ming Lu CHM	Chairman	-	-
Tsu Te Li BRD	Director/Board Member	-	-
Wan Chun Chen BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIAMOND BIOFUND INC.	+0.30%	-3.98%	-13.99%	-76.66%	447M
BLACKROCK, INC.	+1.05%	+2.41%	+0.11%	+66.89%	180B
UBS GROUP AG	+0.36%	+1.79%	+37.54%	+111.69%	165B
BANK OF NEW YORK MELLON CORPORATION (THE)	+1.63%	+2.64%	+57.25%	+254.12%	111B
BROOKFIELD CORPORATION	-0.05%	-0.02%	+3.56%	+102.53%	102B
BROOKFIELD ASSET MANAGEMENT LTD.	-1.44%	+2.93%	-12.06%	+60.63%	87.13B
STATE STREET CORPORATION	+1.54%	+1.64%	+70.62%	+158.02%	52.22B
AMERIPRISE FINANCIAL, INC.	+0.37%	+0.72%	+9.30%	+64.06%	49.91B
3I GROUP PLC	+0.46%	-1.67%	-30.89%	+47.80%	38.07B
NORTHERN TRUST CORPORATION	+1.89%	+3.77%	+50.20%	+139.43%	35B
Average	+0.61%	+0.68%	+17.16%	+92.85%	82.01B
Weighted average by Cap.	+0.58%	+1.44%	+20.21%	+112.67%

	2024	2025
Net sales	-2.23B -69.11M -59.88M -56.1M -51.17M -96.2M -6.59B -97.68M -660M -258M -3.3B -259M -254M -11.01B	-1.07B -33.28M -28.83M -27.02M -24.64M -46.33M -3.17B -47.04M -318M -124M -1.59B -125M -122M -5.3B
Net income	-2.52B -78.08M -67.65M -63.38M -57.81M -109M -7.45B -110M -745M -291M -3.73B -293M -287M -12.43B	-1.17B -36.43M -31.56M -29.57M -26.97M -50.71M -3.47B -51.49M -348M -136M -1.74B -137M -134M -5.8B
Net Debt	-5.01B -155M -135M -126M -115M -216M -14.82B -220M -1.48B -580M -7.42B -584M -571M -24.75B	-3.8B -118M -102M -95.59M -87.18M -164M -11.23B -166M -1.12B -439M -5.62B -442M -432M -18.75B